Phyllis Chan

11PUBLICATIONS
31CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)AllergyPredictive and prognostic markersMolecular targetsPharmaceutical delivery technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Feb 17, 2026
Model-Based Meta-Analysis of Overall Survival in Vulnerable Platinum-Ineligible NSCLC Populations.

Joseph Chen, Russ Wada, Nancy Zhang

|Dec 23, 2025
Revisiting the Anti-Drug Antibody Assay Drug Tolerance of a Commercial Biological Product.

James Zanghi, Nancy Yu, Benjamin T Andrews

|Feb 05, 2025
Population Pharmacokinetics and Exposure-Response of Subcutaneous Atezolizumab in Patients With Non-Small Cell Lung Cancer.

Phyllis Chan, Stephanie N Liu, Nathalie Gosselin

|Oct 25, 2023
Comparison of two-stage and joint TGI-OS modeling using data from six atezolizumab clinical studies in patients with metastatic non-small cell lung cancer.

Antonio Gonçalves, Mathilde Marchand, Phyllis Chan

|May 22, 2023
Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework.

Colby S Shemesh, Phyllis Chan, Mathilde Marchand

|Jan 03, 2023
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.

René Bruno, Mathilde Marchand, Kenta Yoshida

Pageof 2

Frequent Collaborators

4 joint publications

René Bruno

3 joint publications

Mathilde Marchand

3 joint publications

Benjamin Wu

2 joint publications

Kenta Yoshida